These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 27742735)

  • 1. β-Lactamases: A Focus on Current Challenges.
    Bonomo RA
    Cold Spring Harb Perspect Med; 2017 Jan; 7(1):. PubMed ID: 27742735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Lactamases and β-Lactamase Inhibitors in the 21st Century.
    Tooke CL; Hinchliffe P; Bragginton EC; Colenso CK; Hirvonen VHA; Takebayashi Y; Spencer J
    J Mol Biol; 2019 Aug; 431(18):3472-3500. PubMed ID: 30959050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress toward inhibitors of metallo-β-lactamases.
    McGeary RP; Tan DT; Schenk G
    Future Med Chem; 2017 May; 9(7):673-691. PubMed ID: 28504895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metallo-β-Lactamase Inhibitors Inspired on Snapshots from the Catalytic Mechanism.
    Palacios AR; Rossi MA; Mahler GS; Vila AJ
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32503337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclic Boronates Inhibit All Classes of β-Lactamases.
    Cahill ST; Cain R; Wang DY; Lohans CT; Wareham DW; Oswin HP; Mohammed J; Spencer J; Fishwick CW; McDonough MA; Schofield CJ; Brem J
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.
    Morinaka A; Tsutsumi Y; Yamada M; Suzuki K; Watanabe T; Abe T; Furuuchi T; Inamura S; Sakamaki Y; Mitsuhashi N; Ida T; Livermore DM
    J Antimicrob Chemother; 2015 Oct; 70(10):2779-86. PubMed ID: 26089439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Standard Numbering Scheme for Class C β-Lactamases.
    Mack AR; Barnes MD; Taracila MA; Hujer AM; Hujer KM; Cabot G; Feldgarden M; Haft DH; Klimke W; van den Akker F; Vila AJ; Smania A; Haider S; Papp-Wallace KM; Bradford PA; Rossolini GM; Docquier JD; Frère JM; Galleni M; Hanson ND; Oliver A; Plésiat P; Poirel L; Nordmann P; Palzkill TG; Jacoby GA; Bush K; Bonomo RA
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31712217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. beta-Lactamases of increasing clinical importance.
    Bush K
    Curr Pharm Des; 1999 Nov; 5(11):839-45. PubMed ID: 10539991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
    Watkins RR; Deresinski S
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107
    [No Abstract]   [Full Text] [Related]  

  • 10. SHV-type beta-lactamases.
    Tzouvelekis LS; Bonomo RA
    Curr Pharm Des; 1999 Nov; 5(11):847-64. PubMed ID: 10539992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broad-Spectrum Inhibitors against Class A, B, and C Type β-Lactamases to Block the Hydrolysis against Antibiotics: Kinetics and Structural Characterization.
    Farhat N; Gupta D; Ali A; Kumar Y; Akhtar F; Kulanthaivel S; Mishra P; Khan F; Khan AU
    Microbiol Spectr; 2022 Oct; 10(5):e0045022. PubMed ID: 36069578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural and Functional Aspects of Extended-Spectrum AmpC Cephalosporinases.
    Powers RA
    Curr Drug Targets; 2016; 17(9):1051-60. PubMed ID: 26073861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Syntheses and studies of new forms of N-sulfonyloxy β-lactams as potential antibacterial agents and β-lactamase inhibitors.
    Carosso S; Miller MJ
    Bioorg Med Chem; 2015 Sep; 23(18):6138-47. PubMed ID: 26321604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.
    Bebrone C; Lassaux P; Vercheval L; Sohier JS; Jehaes A; Sauvage E; Galleni M
    Drugs; 2010 Apr; 70(6):651-79. PubMed ID: 20394454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E
    Acta Med Croatica; 2004; 58(4):307-12. PubMed ID: 15700687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-lactam antibiotics: An overview from a medicinal chemistry perspective.
    Lima LM; Silva BNMD; Barbosa G; Barreiro EJ
    Eur J Med Chem; 2020 Dec; 208():112829. PubMed ID: 33002736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
    Livermore DM; Mushtaq S; Nguyen T; Warner M
    Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Mechanisms of bacterial resistance to beta-lactams by beta-lactamases].
    Sawai T
    Nihon Rinsho; 1997 May; 55(5):1225-30. PubMed ID: 9155179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated functional classification of beta-lactamases.
    Bush K; Jacoby GA
    Antimicrob Agents Chemother; 2010 Mar; 54(3):969-76. PubMed ID: 19995920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past and Present Perspectives on β-Lactamases.
    Bush K
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30061284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.